Ascendis Pharma Adds Growth-Hormone Group To Combination Trial — Regulatory Feedback Delays The Study

The larger study must establish each drug's contribution as Ascendis pursues benefits beyond height for children with achondroplasia.

Share
Ascendis Pharma Adds Growth-Hormone Group To Combination Trial — Regulatory Feedback Delays The Study

Ascendis Pharma, which develops and sells medicines for rare hormone disorders, enlarged its pivotal achondroplasia combination trial and delayed it a few months after U.S. regulatory feedback, President and Chief Executive Officer Jan Mikkelsen said on Thursday's earnings call. Recruitment has started, with the company's results release setting an enrollment target for completion in the second quarter of 2027.

Why Growth Hormone Gets Its Own Group

A question from a Jefferies analyst about the growth-hormone-only group drew Mikkelsen's explanation of the redesign: “Yes, we redesigned it because we got strong regulatory feedback.”

U.S. regulators wanted evidence of what each treatment contributes to the combination. The randomized study therefore includes separate groups receiving TransCon CNP, TransCon growth hormone, or both medicines together.

The added group gives Ascendis a way to compare the combination against each component on its own. Mikkelsen tied the change directly to the study's increased size and later start, saying the company wanted a trial that could support approval.

The Bet Goes Beyond Height

Management's case for the combination rests on its earlier mid-stage study. Mikkelsen said adding growth hormone produced up to three- to four-fold greater improvement in an achondroplasia-specific height measure compared with CNP alone.

He also described improvements in arm span and body proportionality that persisted through 78 weeks, without compromising safety or tolerability. The results release said all 21 children enrolled in that study remain on treatment.

Mikkelsen's ambition extends to the condition's broader complications. He said the company hopes its single-drug and combination treatments could help children avoid surgical procedures, including arm lengthening. That remains a treatment goal underpinning the late-stage program.

Ascendis uses its TransCon technology to release active drugs over time. Its portfolio includes YUVIWEL, the CNP treatment for children with achondroplasia, and SKYTROFA, a growth hormone treatment for children and adults with growth hormone deficiency. YORVIPATH treats adults with hypoparathyroidism.

Commercial Growth Funds The Next Trials

Ascendis reported product revenue of €366 million in the third quarter, up 89% from a year earlier. YORVIPATH contributed €291 million, SKYTROFA €59 million and YUVIWEL €16 million.

Chief Financial Officer Scott Smith raised the operating-cash-flow outlook on Thursday's call to at least €600 million for 2026, matching the results release. Operating cash flow for the third quarter was €189 million.

The company also expects a European Commission decision on TransCon CNP in the fourth quarter of 2026, following favorable committee opinions. If approved, Ascendis plans its first European launch in Germany in the first quarter of 2027.

For the combination program, the next stated milestone is completing enrollment in the second quarter of 2027—with the redesigned study testing whether the two-drug treatment improves on each medicine alone.

Sources

More on Ascendis Pharma

All Ascendis Pharma (ASND) coverage →